These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host. Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552 [TBL] [Abstract][Full Text] [Related]
6. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines. Crafford JE; Lourens CW; Smit TK; Gardner IA; MacLachlan NJ; Guthrie AJ Vaccine; 2014 Jun; 32(29):3611-6. PubMed ID: 24814557 [TBL] [Abstract][Full Text] [Related]
7. Preparation of recombinant African horse sickness virus VP7 antigen via a simple method and validation of a VP7-based indirect ELISA for the detection of group-specific IgG antibodies in horse sera. Maree S; Paweska JT J Virol Methods; 2005 Apr; 125(1):55-65. PubMed ID: 15737417 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants. van Rijn PA; Maris-Veldhuis MA; Grobler M; Wright IM; Erasmus BJ; Maartens LH; Potgieter CA Vaccine; 2020 Oct; 38(45):7108-7117. PubMed ID: 32921506 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination. Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410 [TBL] [Abstract][Full Text] [Related]
10. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform. van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278 [TBL] [Abstract][Full Text] [Related]
11. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV. van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433 [TBL] [Abstract][Full Text] [Related]
16. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959 [TBL] [Abstract][Full Text] [Related]
17. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes. Lulla V; Lulla A; Wernike K; Aebischer A; Beer M; Roy P J Virol; 2016 Aug; 90(16):7405-7414. PubMed ID: 27279609 [TBL] [Abstract][Full Text] [Related]
18. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara. Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178 [TBL] [Abstract][Full Text] [Related]
19. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge. Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J Antiviral Res; 2015 Apr; 116():27-33. PubMed ID: 25643968 [TBL] [Abstract][Full Text] [Related]
20. Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine. Weyer CT; Grewar JD; Burger P; Joone C; Lourens C; MacLachlan NJ; Guthrie AJ Vaccine; 2017 Apr; 35(18):2504-2510. PubMed ID: 28341113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]